Recent IP News

Bayer's Oral Disintegrating Tablet "Levitra" Patent is Obvious

The FDA approved Bayer's drug Levitra for the treatment of erectile disfunction (ED). At that time, Pfizer had a competing drug Viagra and Eli Lilly had Cialis. Read more...

Merck's Antibiotic Drug "Invanz" Patent is Obvious

Merck sued Hospira when the latter sought to market its generic version of Invanz.

The district court found Merck's patent obvious and invalid, even though "none of the three steps of [the patent claim] was individually taught by the prior art." Read more...

US House of Representatives Holds Hearing on Allergan Patent Transfer to St. Regis Mohawk Tribe

Allergan has sought to shield its patents from inter partes review by the USPTO by transferring its patents to the St. Regis Mohawk Tribe, and then licensing the patents back. Read more...

Purdue's "OxyContin" Patent is Obvious

Amneal sought inter partes review in the USPTO to invalidate Purdue's patent for the pain killer OxyContin. The parties were involved in patent litigation over the patent in district court. Read more...

Click here to be added to the
IP Newsletter mailing list.

WHO WE ARE    Shimokaji IP is an intellectual property law firm. The firm's highly experienced patent attorneys, trademark attorneys and other professionals specialize in patent, trademark, copyright, trade secret, and unfair competition.  

WHAT WE DO    We protect your valuable ideas using our expertise in:

The clients we serve range from start-ups and emerging stage to Fortune 100 companies, and from government entities to universities. From our California office, we easily work with our clients throughout the entire United States and Asia.

HOW WE DO IT    Our commitment is exceptional client service, quality work product, and timeliness – from administrative staff to lawyers.

Michael Shimokaji - IP Checklist for a Medical Device Launch